![Kirsten Gruis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kirsten Gruis formerly worked at DiaMedica Therapeutics, Inc., as Chief Medical Officer from 2022 to 2023, PTC Therapeutics GT, Inc., as Chief Medical Officer, and Edgewise Therapeutics, Inc., as Chief Medical Officer.
Dr. Gruis received her undergraduate degree and doctorate degree from the University of Iowa and graduate degree from the University of Michigan School of Public Health.
| Sociétés | Poste | Fin |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 31/08/2023 |
PTC Therapeutics GT, Inc.
 PTC Therapeutics GT, Inc. Medical SpecialtiesHealth Technology Innovates DNA therapeutics, provides long-term efficacy for patients with debilitating & fata diseases | Directeur Technique/Scientifique/R&D | - |
| EDGEWISE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
DiaMedica Therapeutics, Inc.
 DiaMedica Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of therapeutic treatments from novel recombinant proteins | Health Technology |
University of Iowa
 University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan School of Public Health
 University of Michigan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PTC Therapeutics GT, Inc.
PTC Therapeutics GT, Inc. Medical SpecialtiesHealth Technology Innovates DNA therapeutics, provides long-term efficacy for patients with debilitating & fata diseases | Health Technology |
Edgewise Therapeutics, Inc.
 Edgewise Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies for skeletal muscle diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
